Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000789:Angina, Unstable / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000517:prevention & control*; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D000069059:Atorvastatin; D017023:Coronary Angiography; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004562:Electrocardiography; D005260:Female; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000517:prevention & control*; D011379:Prognosis; D011758:Pyrroles / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin